SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing RRP treatment has put pressure on Precigens PAPZIMEOS thesis, with traders debating how much the new entrant could threaten its sales. Some see Precigens commercial head start and full approval as advantages, while others focus on the rivals potential to reduce surgeries and challenge PAPZIMEOS.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A third-quarter earnings beat and raised full-year revenue outlook, driven by demand for Mounjaro and Zepbound, have fueled LLYs move to record highs. Traders largely welcome the GLP-1 growth and analyst upgrades, while some point to reduced profit guidance tied to acquisition charges, rich valuation, and weaker-than-expected Foundayo sales as risks.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two is drawing attention around the anticipated Grand Theft Auto VI launch, with traders debating whether strong sales and ongoing GTA Online spending can support the stock or whether launch expectations are already priced in. Recent weakness has amplified concerns about leaks, piracy, PC-release timing and a possible sell-the-news reaction, while bullish traders view the pullback as an opportunity.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstones exposure to AI infrastructure financing is drawing scrutiny after traders circulated claims that it expects Anthropic to receive a speculative-grade credit rating, against the backdrop of a large chip-financing deal. Some view the credit-risk concerns as warranted, while others accuse Blackstone of issuing a poorly timed hit piece; call-heavy options flow is also being watched.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs run to a 52-week high has traders focused on an expected Q3 earnings report and continued BRIUMVI sales growth. Some attribute the move to earnings expectations and short covering, while others speculate about a buyout; no acquisition has been confirmed, and the earnings date remains uncertain.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons Q3 earnings beat and record refining performance are drawing attention, with traders highlighting strong fuel margins amid tight diesel supplies and geopolitical disruptions. The reaction is broadly bullish, though some traders note the stocks muted response and discuss taking profits or concerns about valuation.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas selection for the S&P 500 is drawing attention, with traders noting potential index-fund buying but debating whether the news could lead to a sell-the-news pullback. The discussion also reflects caution about the stocks recent run and weakness in cybersecurity shares.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a broad tech and semiconductor selloff as traders reassess whether heavy AI infrastructure spending can generate sufficient returns, alongside weak tech earnings and concerns about financing. The community is split between calling the decline a capitulation-driven buying opportunity and warning that the AI trade could face further downside.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicares quarterly recalculations could reduce DefenCath reimbursement in 2027 has fueled concern about pricing and sales, alongside a sharp share-price decline. Traders dispute how much weight to give DaVitas preliminary outlook, arguing that CMSs finalized rate points to a more stable picture, while others remain concerned about reimbursement and adoption.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys quarterly results and upbeat next-quarter outlook are driving attention: subscriber growth and improving gross margins outweighed revenue and earnings misses for many traders. The sharp rally has surprised some investors, while skeptics question whether higher costs and the reported misses justify the move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunocore Hldgs Q2 2026 Earnings Call Transcript

Immunocore Hldgs (NASDAQ:IMCR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below.
Benzinga APIs provide real-time access toread more...

Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.

Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?

Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.

IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.

Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?

Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.

IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss

Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.

Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues

IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.

Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak 

Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.

Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?

Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. the firm's lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Immunocore Holdings plc - ADR

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$30.49
Prev Close	$31.27
Open	$31.00
Dividend Yield	0.00%
50-Day Moving Average	$32.37
Beta	0.73
Avg. Volume	386,601.86
PE Ratio	N/A

52-Week High	$40.71
52-Week Low	$27.50
Market Capitalization	$1.57B
EPS (Annual)	N/A
Price to Book	3.76
Revenue Per Employee	$765,173.26

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMCR Fundamentals